Mineralys Therapeutics Inc. (NASDAQ: MLYS) reported subgroup analyses from its Phase 3 Launch-HTN trial showing lorundrostat demonstrated blood pressure reductions ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE